Last updated: March 2026
Retatrutide produced the highest weight loss of any obesity drug ever tested (24.2% in Phase 2 trials), but its most common side effects — nausea (up to 46%), diarrhea (21%), and vomiting (20%) — are dose-dependent and consistent with other GLP-1 agonists. Most improve within 4–8 weeks.
Every reported adverse event from the Phase 2 trial (Jastreboff et al., NEJM 2023). Real numbers, by dose group, with nothing minimized.
Incidence rates by dose group from the Phase 2 trial (Jastreboff et al., NEJM 2023, N=338, 48 weeks). The most common reason participants reported adverse events.
Source: Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. Per-dose GI side effect rates from the published safety table.
Side effects scale with dose. The most dramatic jump occurs between 4 mg and 8 mg, where nausea increases from 36% to 44%.
The consistent finding across retatrutide trials is that gastrointestinal side effects are worst during dose escalation (typically the first 4–8 weeks at each new dose level) and improve once participants stabilize at a maintenance dose. Starting at 2 mg rather than 4 mg significantly reduced nausea incidence, even when participants ultimately reached the same maintenance dose.
Starting dose (1–2 mg). GI side effects begin but are generally mild. Body adapts to GLP-1 receptor activation.
Side effects peak during titration to higher doses. Nausea, vomiting, and diarrhea most intense during this phase. Gradual escalation reduces severity.
Most GI symptoms diminish substantially. Body adapts to incretin receptor activation. Heart rate may peak around week 24 before declining.
Side effects generally stabilized at lower levels. Participants who tolerated escalation typically maintained good tolerability throughout.
The vast majority of reported side effects were mild to moderate. Severe events were rare and serious adverse events occurred at equal rates to placebo.
Tolerable without intervention. Resolved on their own or with minor dietary adjustments.
Required some management (e.g., dietary changes, anti-nausea measures) but did not require discontinuation.
Led to dose reduction or discontinuation. Rare in the context of the overall trial population.
Ranged from 6% to 16% across retatrutide groups vs. 0% for placebo (Jastreboff et al., NEJM 2023).
Note: Severity distribution is estimated based on published trial descriptions stating "most side effects were mild to moderate" and "severe events were rare." Exact severity counts per category were not published in the primary NEJM paper. Discontinuation range of 6–16% comes directly from the trial safety data (Table 3 of Jastreboff et al., NEJM 2023).
In the Phase 2 trial, 15 serious adverse events were reported in 13 participants — a rate of 4% in both the retatrutide and placebo groups.
Serious adverse event rate across all retatrutide dose groups combined. This is identical to the placebo rate, suggesting these events may not be causally related to the drug.
Serious adverse event rate in participants receiving placebo. Parity with the retatrutide group is notable but does not rule out drug-related risk in larger populations.
Cross-trial comparison at highest studied doses. These are different drugs, different trials, different populations — interpret with caution.
⚠️ Caveat: Cross-trial comparisons have inherent limitations. Different patient populations, different escalation protocols, different endpoints. Sources: Retatrutide (Jastreboff et al., NEJM 2023), Tirzepatide (SURMOUNT-1, NEJM 2022), Semaglutide (STEP-1, NEJM 2021).
Evidence-based strategies observed in clinical trial protocols and GLP-1 class experience.
Clinical trials showed that starting at 2 mg and escalating gradually significantly reduced nausea incidence vs. faster titration. Patience during escalation is key.
GLP-1 activation slows gastric emptying. Smaller, more frequent meals prevent the "too full" sensation that triggers nausea and discomfort.
Diarrhea and vomiting increase dehydration risk. Electrolyte supplementation is important, especially during the first weeks of dose escalation.
High-fat meals exacerbate GI symptoms. Lean proteins, complex carbs, and easily digestible foods are better tolerated during titration.
Many trial participants found that evening injections allowed peak nausea to occur overnight during sleep, improving daytime tolerability.
Ginger supplements, peppermint tea, and bland foods (crackers, toast) can help manage nausea. Persistent vomiting (>24 hours) warrants medical attention.
Commonly recommended supplements for managing GLP-1 medication side effects.
Retatrutide is still investigational. There are significant gaps in the safety data that only time and larger trials can fill.
The Phase 2 trial ran for 48 weeks. Phase 3 (TRIUMPH) trials extend to 68 weeks, but we still have no multi-year safety data. Many metabolic drugs require years of use — we simply don't know what happens beyond one year.
The TRIUMPH program includes multiple Phase 3 trials. TRIUMPH-4 (68 weeks, N=445) reported results in late 2025, but the full safety database from all TRIUMPH trials has not been published. Larger trials may reveal rare side effects not seen in Phase 2.
All GLP-1 receptor agonists carry a black box warning about thyroid C-cell tumors based on rodent studies. It is unknown whether retatrutide's additional glucagon receptor activity changes thyroid risk. Long-term thyroid monitoring data is not yet available.
One case of acute pancreatitis occurred at 12 mg in Phase 2. All incretin-based drugs carry this concern. Whether retatrutide's triple-agonist mechanism changes pancreatitis risk vs. dual or single agonists remains unknown.
No dedicated cardiovascular outcome trial (CVOT) has been completed for retatrutide. Semaglutide has proven CV benefits (SELECT trial). Whether retatrutide provides similar cardiovascular protection is unknown.
Phase 3 data revealed dysesthesia (tingling/skin sensitivity) in ~21% at 12 mg — a unique finding not prominent with other GLP-1 drugs. The mechanism is not yet established and long-term neurological effects are unknown.
Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly. It is currently in Phase 3 clinical trials and is not available by prescription outside of clinical trials.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA. Side effect data is from clinical trials and may not reflect real-world experience. Always consult with a qualified healthcare provider before starting any medication. Data sourced from Jastreboff et al., NEJM 2023.
Data from respective Phase 2/3 clinical trials. Rates are approximate and represent highest-dose groups.
Sources: Jastreboff et al. NEJM 2023 (retatrutide); STEP-1 trial NEJM 2021 (semaglutide); SURMOUNT-1 NEJM 2022 (tirzepatide).
The most common retatrutide side effects are nausea (affecting up to 46% of participants at the highest 12mg dose), diarrhea (21%), vomiting (20%), and decreased appetite (16%). These gastrointestinal side effects are consistent with other GLP-1 receptor agonists and typically improve or resolve after the first 4–8 weeks of treatment as the body adjusts.
No, retatrutide is not FDA approved as of 2026. It is currently in Phase 3 clinical trials (TRIUMPH program) for obesity and type 2 diabetes. It was developed by Eli Lilly and showed exceptional Phase 2 results, but formal FDA approval is expected no earlier than 2026–2027.
Phase 2 clinical trial data showed participants lost an average of 24.2% of body weight at the highest dose (12mg) over 48 weeks — the highest weight loss percentage ever recorded in an obesity drug trial. At 4mg, participants lost approximately 8.7%, and at 8mg, approximately 17.5%.
In Phase 2 trials, retatrutide was tested at 1mg, 4mg, 8mg, and 12mg weekly subcutaneous doses. The highest efficacy was seen at 12mg. However, as of 2026, retatrutide is still investigational and there is no officially approved dosing protocol — all Phase 3 dosing details are determined by Eli Lilly's trial protocols.
Based on Phase 2 clinical trial data, retatrutide appears generally safe with a side effect profile consistent with other GLP-1/GIP agonists. The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting) and were dose-dependent. No serious unexpected safety signals emerged in Phase 2, but long-term safety data is still being collected in Phase 3 trials.